Improved hepatitis delta virus genome characterization by single molecule full-length genome sequencing combined with VIRiONT pipeline.

HDV editing genotyping hepatitis delta virus (HDV) local pipeline long-read sequencing whole-genome sequencing

Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
03 2023
Historique:
revised: 08 02 2023
received: 30 09 2022
accepted: 28 02 2023
medline: 30 3 2023
pubmed: 8 3 2023
entrez: 7 3 2023
Statut: ppublish

Résumé

Hepatitis B virus (HBV) and hepatitis D virus (HDV) coinfection confers a greater risk for accelerated liver disease progression. Full-length characterization of HDV genome is necessary to understand pathogenesis and treatment response. However, owing to its high variability and tight structure, sequencing approaches remain challenging. Herein, we present a workflow to amplify, sequence, and analyze the whole HDV genome in a single fragment. Sequencing was based on the Oxford Nanopore Technologies long-read sequencing followed by a turnkey analysis pipeline (VIRiONT, VIRal in-house ONT sequencing analysis pipeline) that we developed and make available online for free. For the first time, HDV genome was successfully amplified and full-length sequenced in a single fragment, allowing accurate subtyping from 30 clinical samples. High variability of edition, a crucial step in viral life cycle, was found among samples (from 0% to 59%). Additionally, a new subtype of HDV genotype 1 was identified. We provide a complete workflow for assessment of HDV genome at full-length quasispecies resolution overcoming genome assembly issues and helping to identify modifications throughout the whole genome. This will help a better understanding of the impact of genotype/subtype, viral dynamics, and structural variants on HDV pathogenesis and treatment response.

Identifiants

pubmed: 36879535
doi: 10.1002/jmv.28634
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28634

Informations de copyright

© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

Références

Yurdaydın C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepatitis. 2010;17:749-756.
Farci P, Niro G. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228-236.
Caredda F, Rossi E, Monforte A, et al. Hepatitis B virus-associated coinfection and superinfection with agent: indistinguishable disease with different outcome. J Infect Dis. 1985;151:925-928.
Roulot D, Brichler S, Layese R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta. J Hepatol. 2020;73:1046-1062. doi:10.1016/j.jhep.2020.06.038
Tseligka ED, Clément S, Negro F. HDV pathogenesis: unravelling ariadne's thread. Viruses. 2021;13:778.
Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68:512-521.
Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523-532.
Stockdale AJ, Kreuels B, Henrion MRY, Giorgi E, Kyomuhangi I, Geretti AM. Hepatitis D prevalence: problems with extrapolation to global population estimates. Gut. 2020;69:396-397.
Wedemeyer H, Negro F. Devil hepatitis D: an orphan disease or largely underdiagnosed? Gut. 2019;68:381-382.
Chen PJ, Kalpana G, Goldberg J, et al. Structure and replication of the genome of the hepatitis delta virus. Proc Natl Acad Sci U S A. 1986;83:8774-8778.
Le Gal F, Brichler S, Drugan T, et al. Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains. Hepatology. 2017;66:1826-1841.
Hsu C-W, Juang HH, Kuo CY, et al. Structural pattern differences in unbranched rod-like RNA of hepatitis delta virus affect RNA editing. Viruses. 2019;11:934.
Sureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol. 2016;64:S102-S116.
Casey JL. Control of ADAR1 editing of hepatitis delta virus RNAs. Curr Top Microbiol Immunol. 2012;353:123-143.
Dziri S, Rodriguez C, Gerber A, et al. Variable in vivo hepatitis D virus (HDV) RNA editing rates according to the HDV genotype. Viruses. 2021;13:1572.
Wang W, Lempp FA, Schlund F, et al. Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates. J Hepatol. 2021;75:311-323. doi:10.1016/j.jhep.2021.03.025
Ivaniushina V, Radjef N, Alexeeva M, et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol. 2001;82:2709-2718.
Abeywickrama-Samarakoon N, Cortay JC, Sureau C, et al. Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication. Nat Commun. 2020;11:419.
Homs M, Rodriguez-Frias F, Gregori J, et al. Evidence of an exponential decay pattern of the hepatitis delta virus evolution rate and fluctuations in quasispecies complexity in long-term studies of chronic delta infection. PLoS One. 2016;11:e0158557.
Wu S, Zhang Y, Tang Y, et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China. BMC Infect Dis. 2020;20:565.
Hospices Civils de Lyon. Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure. 2021. https://clinicaltrials.gov/ct2/show/NCT03825458
Scholtes C, Icard V, Amiri M, et al. Standardized one-step real-time reverse transcription-PCR assay for universal detection and quantification of hepatitis delta virus from clinical samples in the presence of a heterologous internal-control RNA. J Clin Microbiol. 2012;50:2126-2128.
Kay A, Melo da Silva E, Pedreira H, et al. HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers. J Viral Hepatitis. 2014;21:921-924.
Dohm JC, Peters P, Stralis-Pavese N, Himmelbauer H. Benchmarking of long-read correction methods. NAR Genom Bioinform. 2020;2:lqaa037.
Koren S, Rhie A, Walenz BP, et al. De novo assembly of haplotype-resolved genomes with trio binning. Nat Biotechnol. 2018;36:1174-1182.
Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. Genome Res. 2017;27:722-736.
De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. NanoPack: visualizing and processing long-read sequencing data. Bioinformatics. 2018;34:2666-2669.
Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34:3094-3100.
Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841-842.
Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792-1797.
Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4:406-425.
Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 1980;16:111-120.
Köster J, Rahmann S. Snakemake-a scalable bioinformatics workflow engine. Bioinformatics. 2018;34:3600.
Dény P, Drugan C, Gatherer D, Kay AC, Le Gal F, Drugan T. Hepatitis D Virus clades and genotypes: a practical approach. In: Rizzetto M, Smedile A, eds. Viruses. Vol 4. Il Pensiero Scientifico Editore; 2019:49-80.
Weirather JL, de Cesare M, Wang Y, et al. Comprehensive comparison of pacific biosciences and Oxford nanopore technologies and their applications to transcriptome analysis. F1000Research. 2017;6:100.
Yan Z, Zeng J, Yu Y, et al. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA. J Hepatol. 2017;66:1149-1157.
Luo X, Kang X, Schönhuth A. Strainline: full-length de novo viral haplotype reconstruction from noisy long reads. Genome Biol. 2022;23:29.
Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33:1870-1874.
Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003;52:696-704.
Ronquist F, Teslenko M, van der Mark P, et al. MrBayes 3.2: efficient Bayesian phylogenetic inference and model choice across a large model space. Syst Biol. 2012;61:539-542.
Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39:783-791.
Pflüger LS, Nörz D, Volz T, et al. Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system. JHEP Reports. 2021;3:100356.
Le Gal F, Dziri S, Gerber A, et al. Performance characteristics of a new consensus commercial kit for hepatitis D virus RNA viral load quantification. J Clin Microbiol. 2017;55:431-441.
Radjef N, Gordien E, Ivaniushina V, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004;78:2537-2544.
Butler EK, Rodgers MA, Coller KE, et al. High prevalence of hepatitis delta virus in Cameroon. Sci Rep. 2018;8:11617.
Karimzadeh H, Usman Z, Frishman D, Roggendorf M. Genetic diversity of hepatitis D virus genotype-1 in Europe allows classification into subtypes. J Viral Hepatitis. 2019;26:900-910.
Lucifora J, Delphin M. Current knowledge on hepatitis delta virus replication. Antiviral Res. 2020;179:104812.
Sopena S, Godoy C, Tabernero D, et al. Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing. Virus Res. 2018;243:52-59.
Groc S, Abbate JL, Le Gal F, et al. High prevalence and diversity of hepatitis B and hepatitis delta virus in Gabon. J Viral Hepatitis. 2019;26:170-182.
Zakh R, Churkin A, Totzeck F, et al. A mathematical analysis of HDV genotypes: from molecules to cells. Mathematics. 2021;9:2063.
Rizzetto M. Targeting hepatitis D. Semin Liver Dis. 2018;38:066-072.
Sandmann L, Cornberg M. Experimental drugs for the treatment of hepatitis D. J Exp Pharmacol. 2021;13:461-468.

Auteurs

Caroline Charre (C)

Department of Virology, Hospital Cochin, AP-HP, Paris, France.
Cochin Institute, INSERM U1016, CNRS UMR8104, Paris, France.
Deparment of Virology, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.

Hadrien Regue (H)

Deparment of Virology, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.

Paul Dény (P)

INSERM U1052 - Cancer Research Center of Lyon (CRCL), Lyon, France.
Department of Clinical Microbiology, Avicenne Hospital, Assistance Publique Hôpitaux de Paris, UFR Santé Médecine Biologie Humaine, University Sorbonne Paris Nord, Bobigny, France.

Laurence Josset (L)

Deparment of Virology, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.
University Claude Bernard Lyon 1 (UCBL1), University of Lyon, Lyon, France.
INSERM U1111, CIRI, Lyon, France.

Isabelle Chemin (I)

INSERM U1052 - Cancer Research Center of Lyon (CRCL), Lyon, France.

Fabien Zoulim (F)

INSERM U1052 - Cancer Research Center of Lyon (CRCL), Lyon, France.
University Claude Bernard Lyon 1 (UCBL1), University of Lyon, Lyon, France.
Department of Hepatology, Hospices Civils de Lyon, Lyon, France.

Caroline Scholtes (C)

Deparment of Virology, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.
INSERM U1052 - Cancer Research Center of Lyon (CRCL), Lyon, France.
University Claude Bernard Lyon 1 (UCBL1), University of Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH